A detailed history of Assenagon Asset Management S.A. transactions in Moderna, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 13,159 shares of MRNA stock, worth $484,909. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,159
Previous 7,352 78.99%
Holding current value
$484,909
Previous $873,000 0.69%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$63.64 - $125.14 $369,557 - $726,687
5,807 Added 78.99%
13,159 $879,000
Q2 2024

Jul 18, 2024

BUY
$101.21 - $166.61 $85,320 - $140,452
843 Added 12.95%
7,352 $873,000
Q1 2024

Apr 24, 2024

BUY
$85.37 - $115.44 $45,246 - $61,183
530 Added 8.86%
6,509 $693,000
Q4 2023

Jan 17, 2024

SELL
$69.51 - $104.43 $75,279 - $113,097
-1,083 Reduced 15.34%
5,979 $594,000
Q3 2023

Nov 06, 2023

BUY
$96.41 - $126.61 $25,066 - $32,918
260 Added 3.82%
7,062 $729,000
Q2 2023

Jul 25, 2023

SELL
$118.5 - $160.53 $156,183 - $211,578
-1,318 Reduced 16.23%
6,802 $826,000
Q1 2023

Apr 18, 2023

SELL
$135.66 - $197.02 $99,845 - $145,006
-736 Reduced 8.31%
8,120 $1.25 Million
Q4 2022

Jan 12, 2023

BUY
$118.38 - $210.04 $127,258 - $225,793
1,075 Added 13.82%
8,856 $1.59 Million
Q3 2022

Oct 27, 2022

BUY
$118.07 - $194.18 $653,281 - $1.07 Million
5,533 Added 246.13%
7,781 $920,000
Q2 2022

Jul 27, 2022

SELL
$117.13 - $176.59 $94,055 - $141,801
-803 Reduced 26.32%
2,248 $321,000
Q1 2022

Apr 25, 2022

BUY
$126.46 - $235.05 $44,261 - $82,267
350 Added 12.96%
3,051 $526,000
Q4 2021

Feb 01, 2022

SELL
$225.82 - $368.51 $51,035 - $83,283
-226 Reduced 7.72%
2,701 $686,000
Q3 2021

Oct 19, 2021

BUY
$221.9 - $484.47 $649,501 - $1.42 Million
2,927 New
2,927 $1.13 Million

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $14.4B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.